Ko Eric C, Koprowski Christopher D, Dickson-Witmer Diana, Penman Emily, Sorensen Michael, Hanlon Alexandra L, Sammons Sarah, Farach Andrew, Strasser Jon
Department of Radiation Oncology, Helen F. Graham Cancer Center, Christiana Care Health System, Newark, DE 19713, USA.
Brachytherapy. 2010 Jul-Sep;9(3):248-53. doi: 10.1016/j.brachy.2009.12.002. Epub 2010 Feb 13.
We compared patients undergoing partial breast irradiation (PBI) with the MammoSite applicator (Cytyc Corp., Marlborough, MA) to a similar group of patients who underwent whole breast irradiation with external beam radiotherapy.
Stage 0-IIA breast cancer patients satisfying American Brachytherapy Society selection criteria and receiving accelerated PBI with the MammoSite system (n=100) were compared for toxicities with similarly staged patients receiving whole breast irradiation using tangential portals (n=100). The MammoSite applicator treatment was prescribed to a total dose of 34 Gy. External beam doses generally ranged from 60 to 66 Gy.
Based on common toxicity criteria scores for acute toxicities, MammoSite patients experienced less cutaneous toxicity, fatigue, and breast pain and had higher Karnofsky performance status scores during the acute period than external beam patients but experienced more seroma pain during followup. These results were both statistically significant and clinically meaningful.
In our institutional experience, PBI using the MammoSite applicator produces less acute toxicity than external beam radiotherapy of the whole breast but is associated with an increased incidence of seroma pain. The rate of disease recurrence in both cohorts was low.
我们将使用MammoSite施源器（Cytyc公司，马萨诸塞州马尔伯勒）进行部分乳腺照射（PBI）的患者与一组接受全乳外照射放疗的类似患者进行了比较。
将符合美国近距离放射治疗学会选择标准并使用MammoSite系统接受加速PBI的0-IIA期乳腺癌患者（n = 100）与使用切线野接受全乳照射的分期相似的患者（n = 100）进行毒性比较。MammoSite施源器治疗的总剂量规定为34 Gy。外照射剂量一般在60至66 Gy之间。
根据急性毒性的常见毒性标准评分，MammoSite组患者在急性期的皮肤毒性、疲劳和乳腺疼痛较轻，卡诺夫斯基功能状态评分较高，但在随访期间血清肿疼痛较多。这些结果在统计学上具有显著性且在临床上有意义。
根据我们机构的经验，使用MammoSite施源器进行PBI产生的急性毒性比全乳外照射放疗少，但血清肿疼痛的发生率增加。两组的疾病复发率都很低。
